Chordia Therapeutics Inc. (Headquarters: Fujisawa, Kanagawa Prefecture, Japan; CEO: Hiroshi Miyake) announced data from the Phase 1/2 trial (CTX-712-CL-02) of rogocekib (CTX-712), a CLK inhibitor, for patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), at the European Hematology Association (EHA) Annual Meeting held in Stockholm, Sweden, from June 11 to 14, 2026. To promote understanding among investors and the general public, and to address questions previously received, the company has released a press release, an explanatory video, and supplementary materials. The video clearly explains key results from the clinical data, including patient background, trial design, safety, pharmacokinetics/pharmacodynamics (PK/PD), and initial efficacy. The supplementary materials summarize key points and data interpretations from the presentation.

The presented results suggest pharmacological activity consistent with the mechanism of action of the company's investigational drug, as well as early clinical signals, which are considered valuable insights for determining future development strategies.

Explanatory Video

URL: https://www.youtube.com/watch?v=k8d5OLfrJ1c

About Chordia Therapeutics Inc.

Chordia Therapeutics is a research and development-focused biotech company specializing in oncology, headquartered in Fujisawa, Kanagawa Prefecture. Its lead pipeline candidate, the CLK inhibitor rogocekib (CTX-712), is currently undergoing Phase 1/2 trials in the United States. Rogocekib targets cancer vulnerabilities and holds promise as a potential therapeutic. In addition to rogocekib and the MALT1 inhibitor ocipumaltib (CTX-177), the company is advancing research and development on multiple pipelines, including the CDK12 inhibitor CTX-439 and GCN2 inhibitors.

For more information, please visit the company website: https://www.chordiatherapeutics.com/

Inquiries regarding this release

IR Contact: Yoshira, Chordia Therapeutics Inc.

info@chordiatherapeutics.com

FACT BOX

  • Source: PR TIMES
  • Category: Event
  • Products / services: rogocekib (CTX-712) / ocipumaltib (CTX-177)